ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Cardiovascular Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

15,410Medicare Part D Prescriptions Filled, Including Refills

Rank: 14 out of 1042

$887K Total Retail Price of All Prescriptions

Rank: 21 out of 1042

946 Patients Receiving at Least One Drug in Part D
92% Patients 65 Years and Older
24% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in Texas
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

1% of this provider’s 946 patients filled at least one prescription for a schedule three drug, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$58 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 11.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in Texas
CLOPIDOGREL 2,074 1,944 329 1 1
CARVEDILOL 1,218 1,137 221 2 3
FUROSEMIDE 1,051 1,005 211 3 7
METOPROLOL SUCCINATE 827 795 145 4 2
POTASSIUM CHLORIDE 822 787 140 5 15
CRESTOR 564 521 85 6 12
AMLODIPINE BESYLATE 496 477 87 7 6
ATORVASTATIN CALCIUM 451 432 92 8 5
SIMVASTATIN 445 430 83 9 9
WARFARIN SODIUM 397 386 74 10 10
AMIODARONE HCL 347 342* 82 11 18
RAMIPRIL 316 278 53 12 21
METOPROLOL TARTRATE 310 290 58 13 8
PRAVASTATIN SODIUM 292 271 53 14 14
LISINOPRIL 289 272 48 15 4
ISOSORBIDE MONONITRATE ER 287 282* 52 16 11
NITROSTAT 218 199 172 17 27
MULTAQ 185 180* 31 18 52
LISINOPRIL-HYDROCHLOROTHIAZIDE 181 162 28 19 32
ZETIA 172 159 31 20 28
SPIRONOLACTONE 171 166* 43 21 20
PRADAXA 165 160* 24 22 25
XARELTO 163 158* 43 23 23
AMLODIPINE BESYLATE-BENAZEPRIL 157 152* 27 24 50
LEVOTHYROXINE SODIUM 154 149* 24 25 26
NIASPAN 140 135* 27 26 40
RANEXA 135 123 22 27 29
DILTIAZEM ER 121 116* 23 28 82
ATENOLOL 115 110* 27 29 17
BENICAR 113 97 17 30 55
FENOFIBRATE* 107 107 17 31 43
DILTIAZEM 24HR CD 106 106 23 32 60
DIOVAN 101 101 16 33 19
BUMETANIDE 82 77* 16 34 75
HYDROCHLOROTHIAZIDE 80 75* 18 35 16
KLOR-CON 10 79 66 20 36 94
BRILINTA 78 <11 <11 37 117
ALLOPURINOL 78 67 16 37 74
VALSARTAN-HYDROCHLOROTHIAZIDE 77 77 14 39 38
CILOSTAZOL 72 <11 <11 40 49
LOVASTATIN 71 66* 12 41 51
DIGOX 70 65* 23 42 22
AZOR 70 <11 <11 42 100
EFFIENT 68 63* 12 44 53
LOVAZA 67 67 12 45 62
KLOR-CON M20 64 51 12 46 54
DILTIAZEM 24HR ER 63 58* 22 47 59
CLONIDINE HCL 63 63 19 47 33
DIGOXIN 60 60 11 49 31
PACERONE 59 59 12 50 92
IRBESARTAN 59 <11 <11 50 84
VERAPAMIL ER 55 55 12 52 73
LOSARTAN POTASSIUM 55 55 12 52 13
BYSTOLIC 53 48* 15 54 24
COREG CR 52 <11 <11 55 96
BENAZEPRIL HCL 50 <11 <11 56 72
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 5, 2009.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.